Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Thursday morning. The firm issued a hold rating on the stock.

Other research analysts have also recently issued reports about the company. HC Wainwright reiterated a buy rating and issued a $10.00 price target on shares of Ekso Bionics in a research note on Tuesday, July 30th. Lake Street Capital started coverage on Ekso Bionics in a research note on Monday, June 24th. They set a buy rating and a $2.50 price target on the stock.

Ekso Bionics Stock Performance

NASDAQ:EKSO opened at $0.90 on Thursday. The company has a quick ratio of 2.11, a current ratio of 2.42 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $16.30 million, a PE ratio of -0.92 and a beta of 1.51. Ekso Bionics has a twelve month low of $0.62 and a twelve month high of $3.13. The stock’s 50-day simple moving average is $1.10 and its 200 day simple moving average is $1.38.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $4.95 million for the quarter, compared to the consensus estimate of $5.34 million. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. During the same period last year, the firm posted ($0.31) earnings per share. On average, analysts anticipate that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.